Company Press Releases Kathleen Otto 3/14/24 Kathleen Otto 3/14/24 NexPoint Trustee Honored for Impactful Leadership in Mutual Fund Governance Read More Kathleen Otto 3/14/24 Kathleen Otto 3/14/24 Form Bio Integrates Google Cloud's AI Models for Healthcare and Life Sciences Research Read More Kathleen Otto 3/13/24 Kathleen Otto 3/13/24 JLL Recognized for Third Consecutive Year by IWBI for Commitment to Health and Well-being Read More Kathleen Otto 3/12/24 Kathleen Otto 3/12/24 EisnerAmper Receives 'Best Audit Firm - Start-Ups' Award Read More Kathleen Otto 3/11/24 Kathleen Otto 3/11/24 Johnson & Johnson Seeks FDA Approval for TREMFYA® in Ulcerative Colitis Treatment Read More Kathleen Otto 3/11/24 Kathleen Otto 3/11/24 DFW Airport Retains Title as Best Large Airport in North America Read More Kathleen Otto 3/6/24 Kathleen Otto 3/6/24 Colossal Biosciences Achieves iPSC Breakthrough for Woolly Mammoth Project Read More Kathleen Otto 3/5/24 Kathleen Otto 3/5/24 Caris Life Sciences Partners with Beat Childhood Cancer Research Consortium to Advance Precision Oncology Read More Kathleen Otto 3/4/24 Kathleen Otto 3/4/24 Mark Cuban's Cost Plus Drug Company to Commence Pharmaceutical Manufacturing in Texas Read More Kathleen Otto 3/4/24 Kathleen Otto 3/4/24 Lantern Pharma's RADR® Surpasses 60 Billion Data Points, Targeting 100 Billion in 2024 Read More Kathleen Otto 3/1/24 Kathleen Otto 3/1/24 Johnson & Johnson's RYBREVANT® Receives FDA Approval for First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations Read More Kathleen Otto 2/28/24 Kathleen Otto 2/28/24 Form Bio and Ginkgo Bioworks Unite to Revolutionize AAV Gene Therapy Development Read More Kathleen Otto 2/27/24 Kathleen Otto 2/27/24 SHARx Teams Up with Mark Cuban's Cost Plus Drug Company to Expand Access to Specialty Medications Read More Kathleen Otto 2/26/24 Kathleen Otto 2/26/24 Johnson & Johnson's IMBRUVICA® Receives FDA Approval for Expanded Use Read More Kathleen Otto 2/26/24 Kathleen Otto 2/26/24 Island Pharmaceuticals CEO Updates on ISLA-101: Phase 1 Results, Funding, and Phase 2 Plans Read More Kathleen Otto 2/22/24 Kathleen Otto 2/22/24 Alpha Cognition Inc. Files New Patent for ALPHA-1062, Extending Protection for Alzheimer's Treatment Read More Kathleen Otto 2/21/24 Kathleen Otto 2/21/24 ReCode Therapeutics Initiates Phase 1 Trial of Inhaled mRNA Therapy RCT2100 for Cystic Fibrosis Read More Kathleen Otto 2/21/24 Kathleen Otto 2/21/24 Colossal Biosciences and Underdog Films Team Up for De-Extinction Docuseries Read More Kathleen Otto 2/20/24 Kathleen Otto 2/20/24 RSM's FamilySight Platform Earns Recognition for Revolutionizing Family Office Operations Read More Kathleen Otto 2/16/24 Kathleen Otto 2/16/24 UiPath and Deloitte Unveil Smart Finance for Growth Companies to Accelerate Automation Read More Newer Posts Older Posts
Kathleen Otto 3/14/24 Kathleen Otto 3/14/24 NexPoint Trustee Honored for Impactful Leadership in Mutual Fund Governance Read More
Kathleen Otto 3/14/24 Kathleen Otto 3/14/24 Form Bio Integrates Google Cloud's AI Models for Healthcare and Life Sciences Research Read More
Kathleen Otto 3/13/24 Kathleen Otto 3/13/24 JLL Recognized for Third Consecutive Year by IWBI for Commitment to Health and Well-being Read More
Kathleen Otto 3/12/24 Kathleen Otto 3/12/24 EisnerAmper Receives 'Best Audit Firm - Start-Ups' Award Read More
Kathleen Otto 3/11/24 Kathleen Otto 3/11/24 Johnson & Johnson Seeks FDA Approval for TREMFYA® in Ulcerative Colitis Treatment Read More
Kathleen Otto 3/11/24 Kathleen Otto 3/11/24 DFW Airport Retains Title as Best Large Airport in North America Read More
Kathleen Otto 3/6/24 Kathleen Otto 3/6/24 Colossal Biosciences Achieves iPSC Breakthrough for Woolly Mammoth Project Read More
Kathleen Otto 3/5/24 Kathleen Otto 3/5/24 Caris Life Sciences Partners with Beat Childhood Cancer Research Consortium to Advance Precision Oncology Read More
Kathleen Otto 3/4/24 Kathleen Otto 3/4/24 Mark Cuban's Cost Plus Drug Company to Commence Pharmaceutical Manufacturing in Texas Read More
Kathleen Otto 3/4/24 Kathleen Otto 3/4/24 Lantern Pharma's RADR® Surpasses 60 Billion Data Points, Targeting 100 Billion in 2024 Read More
Kathleen Otto 3/1/24 Kathleen Otto 3/1/24 Johnson & Johnson's RYBREVANT® Receives FDA Approval for First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations Read More
Kathleen Otto 2/28/24 Kathleen Otto 2/28/24 Form Bio and Ginkgo Bioworks Unite to Revolutionize AAV Gene Therapy Development Read More
Kathleen Otto 2/27/24 Kathleen Otto 2/27/24 SHARx Teams Up with Mark Cuban's Cost Plus Drug Company to Expand Access to Specialty Medications Read More
Kathleen Otto 2/26/24 Kathleen Otto 2/26/24 Johnson & Johnson's IMBRUVICA® Receives FDA Approval for Expanded Use Read More
Kathleen Otto 2/26/24 Kathleen Otto 2/26/24 Island Pharmaceuticals CEO Updates on ISLA-101: Phase 1 Results, Funding, and Phase 2 Plans Read More
Kathleen Otto 2/22/24 Kathleen Otto 2/22/24 Alpha Cognition Inc. Files New Patent for ALPHA-1062, Extending Protection for Alzheimer's Treatment Read More
Kathleen Otto 2/21/24 Kathleen Otto 2/21/24 ReCode Therapeutics Initiates Phase 1 Trial of Inhaled mRNA Therapy RCT2100 for Cystic Fibrosis Read More
Kathleen Otto 2/21/24 Kathleen Otto 2/21/24 Colossal Biosciences and Underdog Films Team Up for De-Extinction Docuseries Read More
Kathleen Otto 2/20/24 Kathleen Otto 2/20/24 RSM's FamilySight Platform Earns Recognition for Revolutionizing Family Office Operations Read More
Kathleen Otto 2/16/24 Kathleen Otto 2/16/24 UiPath and Deloitte Unveil Smart Finance for Growth Companies to Accelerate Automation Read More
